ClinicalTrials.gg
CompletedNCT00091793Updated Dec 31, 2010Results posted

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

A Phase 3 interventional study of AMG 162 and Placebo in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged Up to 90 Years. Per ClinicalTrials.gov, last updated 2010-12-31.

Sponsored by Amgen · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
Up to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
14th of 31
332 · median 278
Started
2004
with 1 other
Phase 3
17 of 31
1 open now
Registered
2nd of 31
by date
Lead sponsor
12 of 31
Amgen

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 14th largest by enrollment, is one of 2 that started in 2004, is one of 17 in phase 3, and was the 2nd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: Up to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Osteoporosis
  • Postmenopausal
04

Who can participate

Ages eligible
Up to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria

- women with Osteopenia (lumbar spine bone mineral density T-score between 1.0 and -2.5)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (actual)

Study arms

  • Experimental
    AMG 162

    60 mg/mL denosumab given day 1, month 6, month 12 and month 18

    Drug: AMG 162

  • Placebo comparator
    Placebo

    Placebo given day 1, month 6, month 12 and month 18

    Drug: Placebo

Interventions

  • 60 mg/mL denosumab given day 1, month 6, month 12 and month 18

  • DrugPlacebo

    Placebo given at day 1, month 6, month 12 and month 18

06

What researchers measure

Primary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 Months

Secondary outcomes

  1. Total Hip Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 Months

  2. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 Months

  3. Trochanter Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 months

  4. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 months

  5. Total Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 24

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 months

  6. Distal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 24

    Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).

    Time frame: 24 months

  7. Distal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24

    Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).

    Time frame: 24 months

  8. Distal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24

    Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).

    Time frame: 24 months

07

Results

Posted Jan 26, 2010

Participant flow

Participant flow — Overall Study
MilestoneDenosumab 60 mg Q6MPlacebo
Started166166
Completed142144
Not completed2422
Withdrew: Adverse event12
Withdrew: Withdrawal by subject1015
Withdrew: Ineligibility determined20
Withdrew: Lost to follow-up75
Withdrew: Noncompliance20
Withdrew: Other20

Outcome measures

PrimaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 Months
Reported as:
Least squares mean · Percent Change from Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 246.5 (5.8 to 7.2)-.6 (-1.2 to .1)
Statistical analysis
  • Denosumab 60 mg Q6M vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 7 · 95% CI 6.2 to 7.8
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 Months
Reported as:
Least squares mean · Percent Change from Baseline
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Total Hip Bone Mineral Density Percent Change From Baseline at Month 243.4 (3.0 to 3.7)-1.1 (-1.5 to -.8)
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 Months
Reported as:
Least squares mean · Percent Change from Baseline
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 242.8 (2.3 to 3.3)-.9 (-1.4 to -.3)
SecondaryTrochanter Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Trochanter Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Trochanter Bone Mineral Density Percent Change From Baseline at Month 245.2 (4.7 to 5.6)-.8 (-1.3 to -.3)
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 241.4 (.9 to 1.9)-2.1 (-2.6 to -1.6)
SecondaryTotal Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 24

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Total Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Total Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 242.4 (1.9 to 2.9)-1.4 (-1.9 to -.8)
SecondaryDistal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 24

Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Distal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Distal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 248.7 (3 to 14.4)-.7 (-6.6 to 5.3)
SecondaryDistal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24

Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Distal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Distal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24.3 (-.1 to .8)-1.4 (-1.8 to -.9)
SecondaryDistal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24

Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Distal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Distal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24.8 (0 to 1.6)-1.9 (-2.6 to -1.1)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—9/165 (5.5%)157/165 (95.2%)
Denosumab 60 mg Q6M—18/164 (11%)156/164 (95.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlaceboDenosumab 60 mg Q6M
PneumoniaInfections and infestations0/1653/164
DiverticulitisInfections and infestations0/1652/164
SepsisInfections and infestations0/1652/164
OsteoarthritisMusculoskeletal and connective tissue disorders0/1652/164
Colitis ischaemicGastrointestinal disorders0/1651/164
Colonic polypGastrointestinal disorders0/1651/164
AppendicitisInfections and infestations0/1651/164
CellulitisInfections and infestations0/1651/164
PyelonephritisInfections and infestations0/1651/164
Urinary tract infectionInfections and infestations0/1651/164
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboDenosumab 60 mg Q6M
ArthralgiaMusculoskeletal and connective tissue disorders42/16541/164
NasopharyngitisInfections and infestations31/16536/164
Back painMusculoskeletal and connective tissue disorders33/16533/164
HeadacheNervous system disorders19/16526/164
Pain in extremityMusculoskeletal and connective tissue disorders20/16524/164
Upper respiratory tract infectionInfections and infestations22/16519/164
ConstipationGastrointestinal disorders8/16518/164
Urinary tract infectionInfections and infestations17/16518/164
InfluenzaInfections and infestations18/16515/164
Shoulder painMusculoskeletal and connective tissue disorders10/16517/164

Baseline characteristics

Age Continuous
Age Continuous(Years)Denosumab 60 mg Q6MPlaceboTotal
Mean59.8 ± 7.458.9 ± 7.559.4 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 60 mg Q6MPlaceboTotal
Female166166332
Male000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008 Jun;93(6):2149-57. doi: 10.1210/jc.2007-2814. Epub 2008 Apr 1. PubMed 18381571 ↗
  • Engelke K, Libanati C, Liu Y, Wang H, Austin M, Fuerst T, Stampa B, Timm W, Genant HK. Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA). Bone. 2009 Jul;45(1):110-8. doi: 10.1016/j.bone.2009.03.669. Epub 2009 Apr 2. PubMed 19345291 ↗
  • Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2. PubMed 21289258 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 11 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2004
First posted
Sep 21, 2004
Start
Aug 2004
Primary completionActual
Feb 2009
CompletionActual
Mar 2009
Results delay requested
Nov 23, 2009
Results first posted
Jan 26, 2010
Last update
Dec 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00091793
Lead sponsor
Amgen
First posted
Sep 21, 2004
Start date
Aug 2004
Primary completion
Feb 2009
Completion
Mar 2009
Results posted
Jan 26, 2010
Last update
Dec 31, 2010

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion